Clinical Trials Logo
  1. Home
  2. Fatty Liver Disease
  3. NCT05076058

Effects of Tablets of Silybum Marianum, Pueraria Lobate and Salvia Miltiorrhiza on Fatty Liver

Fatty Liver Disease Clinical Trial

Official title:
Effects of Tablets of Silybum Marianum, Pueraria Lobate and Salvia Miltiorrhiza on the Progression of Fatty Liver in Adults: a Double-blinded Randomized Placebo-controlled Clinical Trial

Clinical Trial Summary

Objectives: To examine the effects of tablets of silybum marianum, Pueraria lobate and salvia miltiorrhiza on the progression of fatty liver in patients with fatty liver. Design: a double-blinded randomized placebo-controlled clinical trial. Setting: community residents, Guangzhou city, South China. Participants: a total 118 men and women (18-65 years), with BMI range of 24-30 kg/m2, and with fatty liver screened by ultrasound or MR at baseline. Arms and Interventions: 118 participants were randomly allocated into two arms using a block randomization method. Experimental Arm: tablet of silybum marianum, Pueraria lobate and salvia miltiorrhiza, 3 tablets (1g each) twice a day for 6 months; Placebo Arm: placebo tablets, 3 tablets (1g each) twice a day for 6 months. Outcome Measures: determined at baseline and at 6 months post treatment 1. Primary Outcome Measures: 1) proton density fat fraction of liver assessed by MR; 2) serum liver fibrosis biomarkers: type procollagen III N terminal peptide, hyaluronic acid, laminin, collagen type IV, and glycocholic acid; 3) NAFLD fibrosis score. 2. Secondary Outcome Measures: 1) serum liver function biomarkers: AST, ALT, GGT, ALP, total protein, and bile acids; 2) fasting blood lipids: total triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol; 3) fasting serum glucose and insulin; 4) serum inflammatory factors (hsCRP and IL-6); 5) oxidative stress: SOD and MDA; and 6) body measurements and body fat mass. Data Analyses: Mean changes in the above outcome measures from baseline to 6 months will be compared between the two arms.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05076058
Study type Interventional
Source Sun Yat-sen University
Contact
Status Active, not recruiting
Phase N/A
Start date March 1, 2021
Completion date June 30, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05881005 - NAC- NAFLD And Cushing N/A
Recruiting NCT05220956 - Impact of Time-restricted Feeding in NAFLD N/A
Enrolling by invitation NCT04066608 - Prevalence of Advanced Fibrosis in Patients Living With HIV
Recruiting NCT04302051 - Assessment of Fatty Liver With Thermo-acoustic Device
Recruiting NCT04496895 - The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults N/A
Recruiting NCT05880316 - Prevalence of MAFLD Among Nurses and the Role of Intermittent Fasting N/A
Active, not recruiting NCT05898841 - Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load Phase 4
Not yet recruiting NCT06302049 - Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis Phase 1/Phase 2
Completed NCT05764811 - SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity N/A
Recruiting NCT05421572 - Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Completed NCT04283942 - Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism N/A
Completed NCT01016418 - Bovine Colostrum for Patients With Non Alcoholic Fatty Liver Disease Phase 1/Phase 2
Terminated NCT04175392 - Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis Phase 1/Phase 2
Not yet recruiting NCT04191044 - Portal Hypertension in Non-alcoholic Fatty Liver Disease: Association With Cardiovascular Risk and Identification of Non-invasive Biomarkers (THESIS)
Not yet recruiting NCT06071923 - Effect of Thyroid Disorders in Liver Diseases
Recruiting NCT04525833 - Liver Disease and Other Systemic Diseases
Not yet recruiting NCT05966025 - Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD) Phase 2
Completed NCT04844450 - A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795 Phase 1
Completed NCT04367012 - Fatty Liver Among Employees at Banha University
Completed NCT05694923 - Effect of Sodium Glucose Cotransporter Inhibitors on Non Diabetic Fatty Liver Disease Patients N/A